Net income swung from a $32.9M loss to a $2.4M profit due to tax normalization.
Gross margin declined from 61.5% to 59.3% due to retail price compression.
Secured $60.7 million through a new debt issuance to bolster liquidity.
Medical cannabis rescheduled to Schedule III, removing 280E tax burdens for 2026.
The Q1 2026 filing reveals a company in the midst of a high-stakes transition. The immediate financial impact of the DOJ's rescheduling of medical cannabis is undeniably positive, providing a massive reprieve from the tax burdens that have historically plagued the industry. This has allowed Trulieve to pivot from deep losses to a positive net income, while maintaining a very strong liquidity position. However, the underlying operational data suggests a challenging environment. The decline in retail revenue and the contraction of gross margins indicate that the company is fighting a difficult battle against price erosion. Investors must weigh the massive potential of federal normalization against the reality of a deteriorating retail market and a lingering cloud of federal illegality for adult-use products. The ultimate trajectory of the stock will likely depend on whether the tax savings can outpace the operational headwinds of a maturing, more competitive market.